10 myths you may have heard from your parents - UCHealth

News|Videos|October 16, 2026 Experts address COVID-19 vaccine myths, safety evidence, and how to frame the benefits of vaccination in pregnancy. Welcome to this Contemporary OB/GYN Special Report series on maternal immunization heading into the 2026-27 respiratory season. Across 5 episodes, our host and experts examine what the latest guidance means in practice for obstetric and pediatric clinicians and for the patients they counsel. Related to this articleOctober 16th, 2026Experts look ahead to new maternal vaccines and how to counsel patients on receiving several in one pregnancy. Read moreOctober 14th, 2026Experts discuss how obstetric and pediatric clinicians can coordinate to protect newborns. Read moreOctober 14th, 2026Experts review ACOG's 2026-27 guidance and the RSV window extension for pregnant and postpartum patients. Read moreOctober 15th, 2026Experts discuss common patient concerns about vaccination in pregnancy and strategies to improve uptake. Read moreOctober 13th, 2026On September 9, 2026, certolizumab pegol received FDA Breakthrough Therapy Designation for APS pregnancy; Jane E. Salmon, MD, reviews the IMPACT trial results behind it.

Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.

European Medical Journal news storyPeople living with HIV may experience subtle changes in heart muscle function even when conventional measures of cardiac performance remain normal, according to findings from a systematic review and meta-analysis. Researchers identified significantly impaired global longitudinal strain (GLS) among people with HIV compared with HIV-uninfected individuals, despite preserved left ventricular ejection fraction (LVEF) in both groups. The findings suggest that speckle-tracking echocardiography (STE) could provide additional information about early myocardial dysfunction in this population. Read the full news story here.

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.